drugset / Trial / NCT02596620

Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication

NCT02596620

Completed 164 enrolled Chang Gung Memorial Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth salts are not available. The investigators compare the efficacies of 10-day levofloxacin-based sequential therapy and 10-day triple therapy in the treatment for patients after failure of standard triple therapy and to determine what clinical and bacterial factors influencing the efficacy of salvage regimens.

Timeline

Start
2013-10
Primary completion
2015-10
Completion
2015-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g
Subject Esomeprazole Small molecule 40 mg
Subject Levofloxacin Small molecule 500 mg
Subject Metronidazole Small molecule 500 mg